Searchable abstracts of presentations at key conferences in endocrinology

ea0011p43 | Bone | ECE2006

Quantitative ultrasound at the hand phalanges in patients with acromegaly

Bolanowski M , Pluskiewicz W , Daroszewski J

Acromegaly is associated with various skeletal deformities and in some cases with bone deterioration. The aim of the study was to assess the skeletal status using quantitative ultrasound (QUS) in patients suffering from acromegaly. A group of 38 patients with acromegaly (27 women and 11 men) in mean age of 57.21±9.85 y in various gonadal status was compared with a control group matched for sex, age and body mass. QUS measurements at hand phalanges were performed with DBM ...

ea0011p402 | Diabetes, metabolism and cardiovascular | ECE2006

Flow mediated dilatation and svcam concentration as the markers of endothelial dysfunction in patients with acromegaly

Bolanowski M , Kaluzny M , Daroszewski J , Szuba A

Acromegaly causes various cardiovascular dysfunctions, and cardiovascular complications are the main cause of increased mortality in non-cured acromegalic patients. The aim of the study was assessment of flow mediated dilatation (FMD) and the concentration of soluble vascular cell adhesive molecule (sVCAM) as the selected markers of endothelial dysfunction in patients suffering from acromegaly. The study was carried out in 40 patients with acromegaly in various stages of the d...

ea0049ep775 | Developmental endocrinology | ECE2017

GH influences plasma fasting adropin concentration in patients with turner syndrome

Wikiera Beata , Krawczyk Magdalena , Noczynska Anna , Daroszewski Jacek

Background: Increased adiposity and insulin resistance are conditions frequently observed nowadays. Many hormones are involved in the pathogenesis of the condition but therapeutic options we can offer to the patients are still scant. Each newly discovered peptide give us hope. Adropin (Ad) is a newly discovered metabolic hormone involved in energy homeostasis. This homeostasis is frequently disturbed in patient with Turner Syndrome (TS). Patient with Turner syndrome are unique...

ea0035p1028 | Thyroid (non-cancer) | ECE2014

The role of peroxisome proliferator-activated receptors α polymorphisms in Graves' disease and orbitopathy

Janusz Przemyslaw , Pawlak-Adamska Edyta , Bolanowski Marek , Daroszewski Jacek

Understanding the genetic etiology of Graves’ disease (GD) and Graves’ orbitopathy (GO) is recognized as an urgent priority. Since peroxisome proliferator-activated receptors α (PPARα) exhibit anti-inflammatory and immunomodulatory activity, and are required for the control of the adipose inflammation process their role in the GD and GO pathogenesis has been proposed. Abnormal expression and/or function of PPARα could suppress the inflammatory response...

ea0070aep910 | Thyroid | ECE2020

The use of single dose of rituximab in combination with radiotherapy, in the treatment of Graves’ Orbitopathy – clinical observations

Gojny Łukasz , Moskwa Agnieszka , Bolanowski Marek , Daroszewski Jacek

The treatment of orbitopathy in the course of Graves’ disease (GO, Graves’ Orbitopathy) still remains a serious therapeutic challenge. Modification of risk factors is considered to be the most important and the most effective method of treatment of benign GO. Treatment with intravenous glucocorticosteroid preparations remains the first-line therapy for moderate- to severe GO but is insufficient in some patients. Radiotherapy has been used in active GO therapy for d...

ea0029p1590 | Thyroid (non-cancer) | ICEECE2012

Polymorphism of the PPAR-γ2 gene and Graves’ orbitopathy: the Ala variant confers decreased risk of eye symptoms

Daroszewski J. , Pawlak-Adamska E. , Bolanowski M. , Frydecka I.

Introduction: Peroxisome proliferatior-activated receptor-γ2 (PPAR-γ2) plays a crucial role in adipogenesis and has been shown to be involved in the control of immunoregulation and inflammation. Orbital fibroblast differentiation to adipocytes is a PPAR-γ dependent process essential for pathogenic tissue remodeling in Graves’ orbitopathy (GO). Genetic variation in PPAR-γ2 gene may modulate expression and/or function of molecule encoded by this gene.</p...

ea0026p389 | Thyroid (non cancer) | ECE2011

The CT60 and Jo31 polymorphisms of CTLA-4 gene are associated with disease progression in Graves’ disease

Daroszewski J , Pawlak-Adamska E , Bolanowski M , Frydecka I

Introduction: Both genetic and environmental factors contribute to clinical manifestation of Graves’ disease including the response to medical therapy. CTLA-4 gene is an important inhibitor of T-cell activation and its polymorphisms may influence the course of the disease.Goal: We investigated the association between CTLA−4 gene polymorphisms: c.49A>G, g.319C>T, g.*642AT(8_33), CT60, and Jo31 and the response to ph...

ea0022p813 | Thyroid | ECE2010

Association of Pro12Ala PPAR-γ gene polymorphism with Graves' orbitopathy

Daroszewski Jacek , Pawlak Edyta , Bolanowski Marek , Frydecka Irena

Introduction: Peroxisome proliferation-activated receptors-γ (PPAR-γ) have been shown to be involved in adipogenesis as well as in immunoregulation and inflammation control. Orbital fibroblast differentiation to adipocytes is a PPAR-γ dependent process essential for pathogenic tissue remodeling in Graves orbitopathy (GO).Purpose: We studied the occurrence and possible associations of the Pro115Gln and Pro12Ala in the ...

ea0014p336 | (1) | ECE2007

Soluble CTLA-4 is increased in Graves’ disease and not related to thyroid status or ophthalmopathy severity

Daroszewski Jacek , Pawlak Edyta , Bolanowski Marek , Slowik Miroslaw , Frydecka Irena

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a B7-binding protein that plays an important role in the down-regulation of T-cell activation. CTLA-4 function is closely associated with predisposition to autoimmune diseases. A native soluble form of CTLA-4 (sCTLA-4) is reported to be present in the sera of patients suffering from autoimmune thyroid disease. In this study we report data on sCTLA-4 concentrations in patients with clinical expression of Graves’ disease.<p c...

ea0081rc1.3 | Rapid Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2022

Plasma amino acid profile in women with polycystic ovary syndrome and its correlation with metabolic disturbances

Paczkowska Katarzyna , Rachon Dominik , Berg Andrzej , Siomkajlo Marta , Rybka Jacek , Kapczynska Katarzyna , Bolanowski Marek , Daroszewski Jacek

Background: Polycystic ovary syndrome (PCOS) is a heterogenous endocrinopathy commonly diagnosed in reproductive age women, predisposing to the development of metabolic disturbances. However, the mechanisms underlying the connection between PCOS and metabolic disorders are still not well understood. The aim of the study was to investigate amino acid (AA) profile in women with PCOS and to assess its relation with metabolic disturbances.Methods: 326 women:...